{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:56Z","timestamp":1790880716189,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Fondazione Cariplo, Fondazione Veronesi, Impact of COVID19 infection on patients affected by inflammatory skin diseases on immunosuppressive therapies","award":["ID 1833073 rif. 2020-1363"],"award-info":[{"award-number":["ID 1833073 rif. 2020-1363"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s13555-022-00732-y","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T10:02:44Z","timestamp":1651053764000},"page":"1303-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-6921","authenticated-orcid":false,"given":"Francesco","family":"Bellinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"732_CR1","unstructured":"2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira. Accessed 17 Feb 2022."},{"key":"732_CR2","first-page":"e470","volume":"34","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, et al. Consensus on the place in therapy of TNF-\u03b1 inhibitors in the treatment of patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34:e470\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"732_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","volume":"31","author":"J Barker","year":"2020","unstructured":"Barker J, Girolomoni G, Egeberg A, Goncalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat. 2020;31:794\u2013800.","journal-title":"J Dermatolog Treat"},{"key":"732_CR4","unstructured":"The European Medicines Agency, The European Commission. Biosimilars in the EU - Information guide for healthcare professionals. In: Prepared jointly by the European Medicines Agency and the European Commission. \u00a9European Med Agency. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 1 Feb 2022."},{"key":"732_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14712598.2020.1812576","volume":"21","author":"F Prignano","year":"2021","unstructured":"Prignano F, Choi J, Pieper B, Iversen L. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opin Biol Ther. 2021;21:75\u201380.","journal-title":"Expert Opin Biol Ther"},{"key":"732_CR6","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/DDDT.S317382","volume":"15","author":"X Zhou","year":"2021","unstructured":"Zhou X, Chen Z, Bi X. An update review of biosimilars of adalimumab in psoriasis\u2014bioequivalence and interchangeability. Drug Des Devel Ther. 2021;15:2987\u201398.","journal-title":"Drug Des Devel Ther"},{"key":"732_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263214","volume":"17","author":"AV Samtsov","year":"2022","unstructured":"Samtsov AV, Bakulev AL, Khairutdinov VR, Kokhan MM, Korotaeva TV, Minullin IK, et al. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: a randomized controlled trial. PLoS ONE. 2022;17: e0263214.","journal-title":"PLoS ONE"},{"key":"732_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454\u201363.","journal-title":"N Engl J Med"},{"key":"732_CR9","unstructured":"2022. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2018\/08\/07\/18A05194\/sg. Accessed 17 Feb 2022."},{"key":"732_CR10","unstructured":"2022. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/02\/03\/20A00685\/sg. Accessed 17 Feb 2022."},{"key":"732_CR11","unstructured":"2022. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2018\/09\/18\/18A05962\/sg. Accessed 17 Feb 2022."},{"key":"732_CR12","unstructured":"2022. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2018\/05\/22\/18A03476\/sg. Accessed 17 Feb 2022."},{"key":"732_CR13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"732_CR14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.19701","volume":"184","author":"T Graier","year":"2021","unstructured":"Graier T, Salmhofer W, Jonak C, Weger W, K\u00f6lli C, Gruber B, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184:1094\u2013105.","journal-title":"Br J Dermatol"},{"key":"732_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/jdv.15978","volume":"34","author":"A Svedbom","year":"2020","unstructured":"Svedbom A, St\u00e5hle M. Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis. J Eur Acad Dermatol Venereol. 2020;34:525\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"732_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2021.1962000","volume":"30","author":"F Ricceri","year":"2021","unstructured":"Ricceri F, Rosi E, Di Cesare A, Scandagli I, Fastame MT, Prignano F. Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single Center study. J Dermatolog Treat. 2021;30:1\u20139.","journal-title":"J Dermatolog Treat"},{"key":"732_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244\u201352.","journal-title":"Br J Dermatol"},{"key":"732_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","volume":"29","author":"DJ No","year":"2018","unstructured":"No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29:460\u20136.","journal-title":"J Dermatolog Treat"},{"key":"732_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.16809","volume":"180","author":"E Sbidian","year":"2019","unstructured":"Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180:86\u201393.","journal-title":"Br J Dermatol"},{"key":"732_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181:450\u20138.","journal-title":"Br J Dermatol"},{"key":"732_CR21","doi-asserted-by":"crossref","unstructured":"van der Kraaij GE, Busard CI, van den Reek J, Menting SP, Musters AH, Hutten BA, et al. Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial. J Invest Dermatol. 2022.","DOI":"10.1016\/j.jid.2022.01.033"},{"key":"732_CR22","doi-asserted-by":"crossref","unstructured":"Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol 2022;157(Suppl. 1 to No. 1):1\u201378.","DOI":"10.23736\/S2784-8671.21.07132-2"},{"key":"732_CR23","doi-asserted-by":"crossref","unstructured":"Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, et al. BADBIR Study Group. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2018;13:775\u201384.","DOI":"10.1016\/j.jid.2017.09.044"},{"issue":"11","key":"732_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40261-021-01089-4","volume":"41","author":"J Barker","year":"2021","unstructured":"Barker J, Baker H, Nadeem A, et al. Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis. Clin Drug Investig. 2021;41(11):1011\u201320.","journal-title":"Clin Drug Investig"},{"key":"732_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/1744666X.2020.1771182","volume":"16","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Geat D, Conti A, et al. TNF-\u03b1 inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Rev Clin Immunol. 2020;16:591\u20138.","journal-title":"Expert Rev Clin Immunol"},{"key":"732_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81:68\u201373.","journal-title":"Ann Rheum Dis"},{"key":"732_CR27","doi-asserted-by":"crossref","unstructured":"Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2021.","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"732_CR28","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/jdv.17348","volume":"35","author":"CC von St\u00fclpnagel","year":"2021","unstructured":"von St\u00fclpnagel CC, Augustin M, D\u00fcpmann L, et al. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases\u2014a systematic review. J Eur Acad Dermatol Venereol. 2021;35:2166\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"732_CR29","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/jdv.14979","volume":"32","author":"L Iversen","year":"2018","unstructured":"Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification\u2014rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32:1930\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"732_CR30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"AB Kimball","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989\u20131004.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"732_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/11539360-000000000-00000","volume":"31","author":"KA Papp","year":"2011","unstructured":"Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, et al. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. Clin Drug Investig. 2011;31:51\u201360.","journal-title":"Clin Drug Investig"},{"key":"732_CR32","first-page":"CD011535","volume":"12","author":"E Sbidian","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00732-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:26:07Z","timestamp":1700504767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00732-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}